NeoImmuneTech, Inc.
An immuno-oncology drug developer with T-cell amplifier NT-I7 and exclusive North American rights to sickle cell disease drug Endari.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 2014 and listed on KOSDAQ in 2021, NeoImmuneTech is a biotech company developing T-cell-based immunotherapies. Its core pipeline NT-I7 (a long-acting IL-7 family T-cell amplifier) is being developed for acute radiation syndrome (ARS) treatment and CAR-T combination therapy, alongside next-generation immuno-oncology pipeline assets NT2020, NT3020, and NT5010 based on its Heterodimer Fc platform. In December 2025 it secured exclusive North American license and distribution rights to Endari®, an FDA-approved sickle cell disease treatment, to pursue parallel commercial revenue, while NT-I7 is in clinical trials for diffuse large B-cell lymphoma, multiple myeloma, non-small cell lung cancer, small cell lung cancer, pancreatic cancer, colorectal cancer, triple-negative breast cancer, and glioblastoma.
Products & technology
- Endari®Sickle cell disease treatment
Clinical trials
data.go.kr1 MFDS clinical trial authorisations · 2023 (Phase 1 1)
- Phase 1NT-I72023-03-16
1 trial site
R&D and key agreements
Source: DART corporate disclosureNT-I7 · 급성방사선증후군(ARS), 거대B세포림프종, 다발성골수종, 비소세포폐암, 소세포폐암, 췌장암, 대장암, 삼중음성유방암, 교모세포종 · 임상시험 진행 중(ARS는 영장류 모델 실험 단계) · Long-acting IL-7 family T-cell amplifier developed for ARS treatment and CAR-T combination therapy
NT2020 · T cell activator based on Heterodimer Fc platform
NT3020 · T cell engager based on Heterodimer Fc platform
NT5010 · TME modifier based on Heterodimer Fc platform
AI reads
MAA server logs · IP-verifiedSomeone asked an AI a question, and it fetched this page live to answer.
Collected for later use. Not a signal of interest.
- OpenAIChatGPT-Useranswer1
Measured since Aug 26, 2026 · 1 AI engines · last read Aug 26, 2026
User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS.
Companies in the same categoryBiotech & Drug Discovery
KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.
Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.
Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.
EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.
A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.
KOSDAQ-listed biotech developing biomarker-driven targeted cancer therapies including lead candidate Vabametkib (ABN401).
KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.
KONEX-listed biotech venture developing new drug candidates with its multi-target fusion protein platform NTIG®
Biotech company developing fusion-protein immuno-oncology and allergy therapeutics, listed on KOSDAQ since 2023.
SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.
A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.
An ADC (antibody-drug conjugate) developer with its ConjuALL platform, having licensed pipeline assets to Janssen, Ono Pharmaceutical, and other global partners.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition